Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PBYI Puma Biotechnology Inc
- Stocks
- Healthcare
- NASDAQ: PBYI
Price (delayed)
$3.31
Market cap
$164.3M
P/E Ratio
4.3
Dividend/share
N/A
EPS
$0.77
Enterprise value
$162.99M
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights
Highlights
The net income has soared by 148% YoY and by 26% from the previous quarter
PBYI's EPS has surged by 133% year-on-year and by 24% since the previous quarter
Key stats
What are the main financial stats of PBYI
Market
Valuations
Earnings
Shares outstanding
49.64M
Market cap
$164.3M
Enterprise value
$162.99M
Price to earnings (P/E)
4.3
Price to book (P/B)
1.69
Price to sales (P/S)
0.71
EV/EBIT
3.77
EV/EBITDA
2.98
EV/Sales
0.7
Revenue
$232.71M
Gross profit
$168.48M
Operating income
$37.25M
Net income
$38.07M
EBIT
$43.23M
EBITDA
$54.66M
Free cash flow
$31.17M
Per share
Balance sheet
Liquidity
EPS
$0.77
EPS diluted
$0.78
Free cash flow per share
$0.63
Book value per share
$1.96
Revenue per share
$4.69
TBVPS
$2.97
Total assets
$196.18M
Total liabilities
$99.07M
Debt
$61.71M
Equity
$97.11M
Working capital
$45.85M
Debt to equity
0.64
Current ratio
1.53
Quick ratio
1.37
Net debt/EBITDA
-0.02
Margins
Efficiency
Dividend
EBITDA margin
23.5%
Gross margin
72.4%
Net margin
16.4%
Operating margin
16%
Return on assets
18.2%
Return on equity
49.3%
Return on invested capital
61.2%
Return on capital employed
39.5%
Return on sales
18.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PBYI stock price
How has the Puma Biotechnology stock price performed over time
Intraday
-1.49%
1 week
-2.65%
1 month
2.32%
1 year
11.82%
YTD
8.52%
QTD
11.82%
Financial performance
How have Puma Biotechnology's revenue and profit performed over time
Revenue
$232.71M
Gross profit
$168.48M
Operating income
$37.25M
Net income
$38.07M
Gross margin
72.4%
Net margin
16.4%
The net income has soared by 148% YoY and by 26% from the previous quarter
Puma Biotechnology's net margin has surged by 141% YoY and by 25% QoQ
The operating income has grown by 43% YoY and by 20% from the previous quarter
The operating margin has grown by 39% YoY and by 19% from the previous quarter
Price vs fundamentals
How does PBYI's price correlate with its fundamentals
Growth
What is Puma Biotechnology's growth rate over time
Valuation
What is Puma Biotechnology stock price valuation
P/E
4.3
P/B
1.69
P/S
0.71
EV/EBIT
3.77
EV/EBITDA
2.98
EV/Sales
0.7
PBYI's EPS has surged by 133% year-on-year and by 24% since the previous quarter
The P/E is 45% lower than the last 4 quarters average of 7.8
Puma Biotechnology's equity has surged by 90% YoY and by 5% QoQ
PBYI's P/B is 78% lower than its 5-year quarterly average of 7.6 and 16% lower than its last 4 quarters average of 2.0
PBYI's P/S is 21% below its 5-year quarterly average of 0.9 but 18% above its last 4 quarters average of 0.6
The revenue has grown by 2.7% YoY
Efficiency
How efficient is Puma Biotechnology business performance
The ROA has soared by 153% YoY and by 28% QoQ
PBYI's ROIC has soared by 115% YoY and by 32% QoQ
PBYI's return on sales is up by 41% year-on-year and by 17% since the previous quarter
Puma Biotechnology's ROE has increased by 39% YoY and by 7% from the previous quarter
Dividends
What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PBYI.
Financial health
How did Puma Biotechnology financials performed over time
The total assets is 98% more than the total liabilities
The total liabilities has contracted by 39% YoY and by 18% from the previous quarter
The total assets has decreased by 8% YoY and by 8% from the previous quarter
Puma Biotechnology's debt is 36% lower than its equity
Puma Biotechnology's equity has surged by 90% YoY and by 5% QoQ
Puma Biotechnology's debt to equity has shrunk by 71% YoY and by 20% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.